Dr. Doug Coyle
Dr. Doug Coyle (he/they)

MA, MSc, PhD

600 Peter Morand (Alta Vista), Room 301K
613-562-5800 ext. 8690


Doug Coyle has been a faculty member within the School since 1995. Doug acted as Interim Director of the School from 2016-18 and was previously director of the graduate program in epidemiology.

Previously he has been based at the Ottawa Health Research Institute and the Centre for Health Economics at the University of York. He is a health economist and obtained his PhD from Brunel University. His research focuses on improving the overall health of the population through the appropriate allocation of health care resources.  He was one of the primary authors of the recent Canadian guidelines for economic evaluation. He has recently developed further guidance with respect to the extrapolation of clinical data and model validation. Doug has published extensively in this area (>250 peer reviewed articles) and has advised CADTH, Health Canada, the Public Health Agency of Canada and various provincial ministries of health with respect to methodology of economic evaluation and in reimbursement decisions relating to health care interventions.  He has served as a member of the Canadian Expert Drug Advisory Committee, Ontario Ministry of Health and Long Term Care's Committee to Evaluate Drugs and Drugs for Rare Diseases Working Group and the Health Economics Advisory Group for CADTH.

Doug currently teaches two graduate courses within SEPH (Health Economic Evaluation and Advanced Health Economic Evaluation).  He has supervised and co-supervised over 40 MSc and PhD students over his career.  Doug was awarded the Career Achievement Award by the Society of Medical Decision Making in 2021.

Selected Publications (past 5 years)

Boczar KE, Beanlands R, Wells G, Coyle D. Cost-effectiveness of colchicine for recurrent cardiovascular events. CJC Open. 202:5:348-356.

Coyle D, Haines A, Lee K. Extrapolating clinical evidence within economic evaluations. Canadian Journal of Health Technologies. 2023:3:5.

Rowlands Snyder EC, McGregor E, Coyle D. Universal ophthalmia neonatorum prophylaxis in Canada: a cost-effectiveness analysis. CMAJ Open. 2023 Jan 17;11(1):E33-E39.

Boczar KE, Beanlands R, Wells G, Coyle D. Cost-effectiveness of canakinumab from a Canadian perspective for recurrent cardiovascular events. CJC Open. 2022 Jan 17;4(5):441-448.

Krewski D, Saunders-Hastings P, Larkin P, Westphal M, Tyshenko MG, Leiss W, Dusseault M, Jerrett M, Coyle D. Principles of risk decision-making. J Toxicol Environ Health. 2022 Jul 4;25(5):250-278

Scarffe AD, Licskai CJ, Ferrone M, Brand K, Thavorn K, Coyle D. Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting. Cost Eff Resour Alloc. 2022 Aug 12;20(1):39.

Pound C, Coyle D. A cost-utility analysis of the impact of electronic nicotine delivery systems on health care costs and outcomes in Canada. Health Promot Chronic Dis Prev Can. 2022 Jan;42(1):29-36.

Gaskin J, Whyte J, Zhou G, Coyle D. Regional cost effectiveness analyses for increasing radon. protection strategies in housing in Canada. 2021: 240; 106752.

Elliott J, Wells GA, Coyle D. The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases. Pharmacoeconomics. 2021 Apr;39(4):479-480.

Coyle K, Quan AML, Wilson LA, Hawken S, Bota AB, Coyle D, Murray JC, Wilson K. Cost-effectiveness of a gestational age metabolic algorithm for preterm and small-for-gestational-age classification. Am J Obstet Gynecol MFM. 2021 Jan;3(1):100279.

Bennett A, Thavorn K, Arendas K, Coyle D, Singh SS. Outpatient uterine assessment and treatment unit in patients with abnormal uterine bleeding: an economic modelling study. CMAJ Open. 2020 Dec 8;8(4):E810-E818.

Abu-Raya B, Coyle D, Bettinger JA, Vaudry W, Halperin SA, Sadarangani M; for members of the Canadian Immunization Monitoring Program, ACTive (IMPACT). Pertussis vaccination in pregnancy in Canada: a cost-utility analysis. CMAJ Open. 2020 Oct 19;8(4):E651-E658.

Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg JM, Greiner W  et al.  HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ. 2020 Dec;21(9):1421-1437.

Coyle D. Who would benefit from average value-based pricing? Health Econ. 2020 Aug;29(8):936-937.

Elliott J, McCoy B, Clifford T, Potter BK, Wells GA, Coyle D. Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. Pharmacoeconomics. 2020 Sep;38(9):971-980.

Gaskin J, Whyte J, Coyle D. An assessment of uncertainty using two different modelling techniques to estimate the cost effectiveness of mitigating radon in existing housing in Canada. Sci Total Environ. 2020 Jul 1;724:138092.

Coyle D, Villeneuve PJ. Economic evaluation of azacitidine in elderly patients with acute myeloid leukemia with high blast counts. Pharmacoecon Open. 2020;4:297–305

Pahuta MA, Werier J, Wai EK, Patchell RA, Coyle D. A technique for approximating transition rates from published survival analyses. Cost Eff Resour Alloc. 2019 Jul 1;17:12.

Elliott J, van Katwyk S, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, Coyle D. Decision models for assessing the cost effectiveness of treatments for pediatric drug-resistant epilepsy: A systematic review of economic evaluations. Pharmacoeconomics. 2019 Oct;37(10):1261-1276

Elliott J, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, Coyle D. Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev. 2019 Mar 27;8(1):75

Pahuta M, Werier J, Wai E, van Walraven C, Coyle D. Back to Bayesian: a strategy to enhance prognostication of metastatic spine disease. Int J Clin Pract 2019 Apr;73(4):e13322.

Pahuta M, Wai E, Werier J, van Walraven C, Coyle D. A general population utility valuation study for metastatic epidural spinal cord compression health states.  Spine 2019 Jul 1;44(13):943-950.

Coyle D. Cost effectiveness of pharmacological treatments for osteoporosis consistent with the revised economic evaluation guidelines for Canada. MDM Policy Practice 2019 30;4(1):2381468318818843.

Pahuta M, Frombach A, Hashem E, Spence S, Sun C, Wai E, Werier J, van Walraven C, Coyle D. The psychometric properties of a self-administered, open-source module for valuing metastatic epidural spinal cord compression utilities. Pharmacoecon Open. 2019 Jun;3(2):197-204.

Research interests

  • Health Economics
  • Economic Evaluation
  • Health Technology Assessment
  • Decision Analysis
  • Prioritization of Research Funding
  • Health Policy